Skip to main content
Beta Drugs Limited logo

Beta Drugs Limited — Investor Relations & Filings

Ticker · BETA ISIN · INE351Y01019 LEI · 984500A89888DB9E6T57 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 431 across all filing types
Latest filing 2021-08-31 Board/Management Inform…
Country IN India
Listing National Stock Exchange of India BETA

About Beta Drugs Limited

https://www.betadrugslimited.com

Beta Drugs Limited specializes in the development, manufacture, and marketing of oncology formulations. The company provides a comprehensive portfolio of anti-cancer drugs across various therapeutic segments, including cytotoxic injectables, lyophilized products, tablets, and capsules. Its manufacturing capabilities encompass a wide range of oncology treatments such as chemotherapy agents and supportive care medications. The organization operates advanced production facilities designed to meet international quality standards, focusing on high-potency active pharmaceutical ingredients and finished dosage forms. The company serves diverse markets through its own branded products and contract manufacturing services, aiming to provide affordable and high-quality cancer care solutions. Its core competency lies in its specialized focus on the oncology niche and its integrated approach to pharmaceutical production.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting held on 31st August 2021 by Beta Drugs Limited. It includes approvals of appointments of auditors (cost auditor, secretarial auditor, internal auditor) for the financial year 2021-22, approval of the draft notice for the Annual General Meeting, and details about the AGM date and book closure. The document also contains detailed profiles of the appointed auditors. There are no financial statements or comprehensive financial data presented, nor is this a transcript or presentation. The document is not a report itself but an official announcement of board decisions and appointments. This fits best under Board/Management Information (MANG) as it announces changes and appointments in company management and auditors. The document length (over 10,000 characters) and content confirm it is not a brief announcement or a report publication notice. Therefore, the classification is MANG with high confidence.
2021-08-31 English
Outcome of Board Meeting
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting held on 31st August 2021 by Beta Drugs Limited. It includes approvals of appointments of auditors (cost auditor, secretarial auditor, internal auditor) for the financial year 2021-22, approval of the draft notice for the Annual General Meeting, and details about the AGM date and book closure. The document also contains detailed profiles of the appointed auditors. This is not a full annual report or financial statement but a formal announcement of board decisions related to governance and audit appointments. It is not a call transcript, earnings release, or any other financial report. The content fits best under Board/Management Information (MANG) as it relates to board meeting outcomes and management decisions regarding appointments and meeting schedules.
2021-08-31 English
Board Meeting — Other business matters
Regulatory Filings Classification · 95% confidence The document text contains only placeholders for omitted pictures and no substantive text or financial data. The true document length is only 174 characters, indicating it is extremely short and contains no report content. There is no indication of any report, announcement, or filing type. Given the lack of content, the document does not fit any specific report category and defaults to Regulatory Filings (RNS) as a fallback category.
2021-08-26 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited's Listing Department. It announces that Beta Drugs Ltd's API plant (Adley Labs Ltd.) has received WHO-GMP approval, which is expected to accelerate growth and expand manufacturing capacity. The content is an update on company operations and approvals, not a financial report or detailed regulatory filing. The document length is short (1614 characters) and it is an announcement of operational progress rather than a formal report or financial statement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-07-19 English
Updates
Call Transcript Classification · 95% confidence The document is a detailed transcript of a Q4 and full-year earnings conference call for Beta Drugs Limited dated May 6, 2021. It includes introductions of management, company background, business segments, product launches, market strategy, and financial performance commentary. The presence of a moderator, management speaking, and a Q&A session format are typical of earnings call transcripts. The document contains substantive discussion of financial results and business outlook, consistent with a Call Transcript (CT). It is not a brief announcement or presentation, nor is it a formal report like an Annual Report or Interim Report. Therefore, the appropriate classification is Call Transcript (CT).
2021-05-11 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a detailed corporate presentation by Beta Drugs Limited, containing extensive information about the company's history, mission, market reach, product portfolio, regulatory expertise, R&D capabilities, and financial performance including EBITDA, revenue, and key financial ratios over multiple years. It is not a formal regulatory filing, audit report, earnings release, or annual report, but rather a comprehensive presentation aimed at investors or stakeholders to provide an overview of the company's business, strategy, and financial health. The presence of disclaimers, market and product details, and financial highlights aligns with the characteristics of an Investor Presentation. The document length (15,000 characters) and content depth support this classification rather than a brief factsheet or announcement.
2021-05-05 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.